tiprankstipranks
uniQure N.V. (QURE)
NASDAQ:QURE

uniQure (QURE) AI Stock Analysis

Compare
1,094 Followers

Top Page

QU

uniQure

(NASDAQ:QURE)

45Neutral
uniQure's stock score is primarily weighed down by financial instability, with persistent losses and liquidity issues posing significant risks. However, the technical analysis shows some support in longer-term trends, and the recent positive corporate event regarding FDA progress for AMT-130 offers a potential catalyst for future growth. Valuation remains weak, reflecting the company's current financial difficulties.
Positive Factors
Market Potential
Huntington's is an area with high unmet need, as there are no disease-modifying therapies currently approved.
Regulatory Approval
The company aligns with the FDA on the components of an accelerated approval BLA for AMT-130 in HD, which could significantly reduce development time.
Negative Factors
Financial Performance
Net loss per share was significantly higher than consensus expectations.

uniQure (QURE) vs. S&P 500 (SPY)

uniQure Business Overview & Revenue Model

Company DescriptionuniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.
How the Company Makes MoneyuniQure generates revenue primarily through strategic collaborations, licensing agreements, and the development and commercialization of its proprietary gene therapy products. Key revenue streams include milestone payments and royalties from partnerships with larger pharmaceutical companies. These collaborations often involve the co-development and commercialization of gene therapies, providing uniQure with financial support and access to broader markets. Additionally, uniQure seeks to commercialize its own therapies, aiming to receive direct sales revenue upon product approval and market launch. The company's earnings are significantly influenced by its ability to successfully advance its product pipeline through clinical trials and regulatory approvals, as well as its capacity to secure and maintain strategic alliances.

uniQure Financial Statement Overview

Summary
uniQure faces considerable financial challenges across all verticals. The income statement shows declining revenue and persistent losses, the balance sheet indicates financial distress with negative equity, and cash flow statements highlight liquidity issues. The company's financial health appears precarious, with significant risks that need addressing.
Income Statement
30
Negative
The income statement reveals substantial volatility in revenue with significant fluctuations over the years. The company experienced a revenue peak in 2021 but faced a sharp decline afterward. Net profit margins have been consistently negative, with a significant net loss in recent periods. The gross profit margin has seen a decline, indicating increased operational challenges. Overall, the company is struggling with profitability and stability.
Balance Sheet
25
Negative
The balance sheet shows high financial risk with negative stockholders' equity in the latest period, indicating insolvency concerns. The debt-to-equity ratio cannot be calculated due to negative equity, but the high total liabilities relative to assets emphasize leverage risk. The equity ratio is negative, reflecting financial instability. Overall, the balance sheet suggests significant financial distress.
Cash Flow
40
Negative
Cash flow analysis indicates negative free cash flow, with recent deterioration in operating cash flow. Despite a large influx from investing activities, it is not sufficient to cover the negative free cash flow, highlighting potential liquidity issues. The ratios related to net income cannot be calculated due to persistent net losses. Overall, cash flow management appears weak with ongoing challenges in generating positive cash flow.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
27.12M15.84M106.48M524.00M37.51M
Gross Profit
25.85M2.21M103.14M499.03M-84.89M
EBIT
-184.29M-282.87M-143.16M310.62M-125.43M
EBITDA
-160.75M-253.10M-108.02M319.00M-126.97M
Net Income Common Stockholders
-239.56M-308.48M-126.79M329.59M-125.02M
Balance SheetCash, Cash Equivalents and Short-Term Investments
367.52M617.89M352.84M556.26M244.93M
Total Assets
556.54M831.69M704.96M809.18M340.39M
Total Debt
66.06M138.41M142.89M135.72M71.54M
Net Debt
-92.87M-102.95M-85.12M-420.53M-173.39M
Total Liabilities
563.29M624.02M228.96M213.40M96.49M
Stockholders Equity
-6.75M207.67M476.01M595.78M243.91M
Cash FlowFree Cash Flow
-186.10M-153.08M-162.75M270.52M-144.31M
Operating Cash Flow
-182.73M-145.93M-145.06M287.96M-134.83M
Investing Cash Flow
162.97M-205.69M-182.73M-67.39M-9.48M
Financing Cash Flow
-59.49M362.72M1.45M94.86M7.44M

uniQure Technical Analysis

Technical Analysis Sentiment
Positive
Last Price13.78
Price Trends
50DMA
14.27
Negative
100DMA
11.66
Positive
200DMA
8.83
Positive
Market Momentum
MACD
-0.34
Negative
RSI
54.78
Neutral
STOCH
85.78
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QURE, the sentiment is Positive. The current price of 13.78 is above the 20-day moving average (MA) of 12.48, below the 50-day MA of 14.27, and above the 200-day MA of 8.83, indicating a neutral trend. The MACD of -0.34 indicates Negative momentum. The RSI at 54.78 is Neutral, neither overbought nor oversold. The STOCH value of 85.78 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for QURE.

uniQure Risk Analysis

uniQure disclosed 62 risk factors in its most recent earnings report. uniQure reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

uniQure Peers Comparison

Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
$13.46B32.108.05%17.35%151.40%
69
Neutral
$9.77B41.8619.71%52.97%
49
Neutral
$6.84B0.05-53.14%2.48%24.49%-3.26%
46
Neutral
$3.63B-19.20%-89.95%-123.71%
45
Neutral
$675.96M-238.46%71.17%23.89%
42
Neutral
$38.57M-270.20%144.50%-141.91%
42
Neutral
$100.68M-76.26%-72.22%51.95%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
QURE
uniQure
13.78
8.96
185.89%
BMRN
BioMarin Pharmaceutical
70.60
-13.79
-16.34%
SRPT
Sarepta Therapeutics
98.37
-25.39
-20.52%
BLUE
Bluebird Bio
3.73
-22.87
-85.98%
ADVM
Adverum Biotechnologies
4.50
-12.80
-73.99%
CRSP
Crispr Therapeutics AG
41.99
-30.02
-41.69%

uniQure Corporate Events

Product-Related AnnouncementsBusiness Operations and StrategyRegulatory Filings and Compliance
uniQure Secures FDA Agreement for AMT-130 Approval
Positive
Dec 10, 2024

uniQure has reached an agreement with the FDA on critical elements for the Accelerated Approval pathway for AMT-130, a promising gene therapy for Huntington’s disease. The FDA’s acceptance of data from Phase I/II studies, along with the use of cUHDRS as a clinical endpoint, marks a significant milestone towards delivering this potential treatment. The company plans to engage further with the FDA in 2025, aiming to expedite the availability of AMT-130, which has shown promising results in slowing disease progression.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.